WFDC2 and ovarian cancer: This study intends to determine these two types of markers in ovarian cancer ascites and to concurrently compare the expression of HE4 in ovarian cancer ascites with the serum CA125 levels of patients to evaluate the relationship between the level of HE4, prognosis, and drug resistance, particularly in patients with recurrent ascites formation to provide a basis for revising the treatment regimen at any time in ovarian cancer or ovarian cancer patients with ascites.